$TNGX News

Canaccord Genuity Maintains Buy on Tango Therapeutics, Raises Price Target to $46

Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60

HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $66

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript

Tango Therapeutics Launches $500M Common Stock Offering

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer - Slideshow

Why Is Tango Therapeutics Stock Soaring Monday?

Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $30

Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24

Jefferies Downgrades Tango Therapeutics to Hold, Raises Price Target to $27

Leerink Partners Maintains Outperform on Tango Therapeutics, Raises Price Target to $55

Wedbush Maintains Outperform on Tango Therapeutics, Raises Price Target to $33

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stifel Maintains Buy on Tango Therapeutics, Raises Price Target to $40

Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines?

Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class’ Potential of Cancer Treatment

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat